After ACIP Debate, CDC Modifies Longstanding Hepatitis B Birth Dose Recommendation
CDC officials say the shift reflects evidence review and informed consent, as public health groups warn of potential downstream effects.
Rezpegaldesleukin Demonstrates Proof of Concept in Phase 2b Trial for Severe Alopecia Areata
Phase 2b REZOLVE-AA trial results show rezpegaldesleukin reduced SALT scores versus placebo in severe alopecia areata, supporting Phase 3 development.
FDA Approves GSK's Depimokimab for Severe Asthma with Th2 Inflammation, First Ultra-Long Acting Biologic
Approval of the novel long-acting mAb was based on the phase 3 SWIFT-1 and SWIFT-2 trials, which showed steep reductions in annualized asthma exacerbations requiring ED or inpatient care.
Hidradenitis Suppurativa Essentials for Primary Care: When to Suspect, Initial Therapy, and When to Refer
This is a topline look for primary care on when to suspect hidradenitis suppurativa, how to stage severity, and when to escalate treatment or refer to dermatology.
With Colonoscopy Capacity Limited, We Need More Momentum Behind Noninvasive Home-Based Tests, Says Mark Fendrick, MD
Fendrick considers the current state of colorectal cancer screening in the US, emphasizing limited colonoscopy capacity and patient preferences for at-home tests.
Chronic Skin Disease Linked to Wide Range of Addictive Behaviors in Pan-European Study
Findings support the importance of integrating behavioral health assessment into dermatology visits, particularly for patients with high quality-of-life impairment.
Hidradenitis Suppurativa: Recognition, Staging, and Management in Primary Care
A practical, evidence-based overview of how to recognize hidradenitis suppurativa early, stage disease severity, and coordinate care before progression.
Investigational Bictegravir–Lenacapavir Single-Tablet Regimen Noninferior to Standard Therapy in Phase 3 ARTISTRY-2 Trial
Gilead's ARTISTRY-2 trial shows a promising single-tablet HIV treatment regimen is noninferior to standard therapy, expanding options for virologically suppressed adults.
Racial Disparity Found in Menopausal Hormone Therapy Prescribing: Daily Dose
Your daily dose of the clinical news you may have missed.
FDA Expands Approval of Flibanserin for Hypoactive Sexual Desire Disorder to Women Younger Than 65 Years
FDA Clears Prescription Digital Therapeutic LumosityRx for Adults with ADHD
The mobile-based program targets cognitive processes underlying attention and is intended for use alongside medication, therapy, or education.
Alzheimer Diseae Drug Development Shifts as Tau Antibody Research Falters
Missed endpoints in midstage tau trials are reshaping the Alzheimer pipeline, with growing focus on inflammatory and vascular pathways. Review them here.
Large National Claims Analysis Underscores Gap Between CGM Eligibility and Real-World Use in Diabetes Care
CGM users experienced fewer ED and inpatient days and better glycemic outcomes, but most eligible adults in this large cohort did not use the technology.
Dupilumab Shows Higher 2-Year Drug Survival Than Other Targeted Therapies for Atopic Dermatitis
Dupilumab shows superior 2-year drug survival rates in atopic dermatitis compared to other biologics and JAK inhibitors, highlighting its effectiveness in treatment persistence.
FDA Approves First Self-Administered Nasal Spray for Adults with PSVT, Milestone Pharmaceuticals Reports
Phase 3 results showed durable conversion benefits with a favorable safety profile, informing real-world management of acute PSVT outside of emergency settings.
New CRC Screening Guidelines Lead to Near 10-Fold Uptake for Adults Aged 45 to 49 Years: Daily Dose
Adult Stimulant Use Accounts for Most Recent Growth in ADHD Prescribing in Canada
A population-based study finds stimulant prescribing accelerated after 2020, with the largest increases among adults and women.
FDA Approves First-in-Class Zolifodacin for Uncomplicated Gonorrhea
Zolifodacin is a single-dose oral treatment option for uncomplicated urogenital gonorrhea and one of the first new classes of drugs for the disease in 20 years.
Opportunities and Limits of Neuromodulation for Excessive Daytime Sleepiness: Highlights of a Narrative Review
A new review examines whether neuromodulation techniques may help address excessive daytime sleepiness across neurologic and psychiatric conditions.
New AI Tool Detects Missed Alzheimer Disease Diagnoses, Reduces Disparities
Findings highlight an AI-based machine-learning approach designed to work around incomplete diagnostic labeling in Alzheimer disease using routine clinical data.
.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "FDA Expands Approval of Flibanserin for Hypoactive Sexual Desire Disorder to Women Younger Than 65 Years")
.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "Dupilumab Shows Higher 2-Year Drug Survival Than Other Targeted Therapies for Atopic Dermatitis")
